Aurobindo Pharma's Hyderabad-based biosimilars facility receives GMP certification from the European Medicines Agency, paving ...

CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The company has has end-to-end capabilities in producing a full range of products from bulk drug substance to fill-finish and ...

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...

Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three ...

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received a Good Manufacturing Practice (GMP) ...

Teva anticipates that the FDA’s decision and EMA’s opinion will come out in the second half of 2025. According to Steffen Nock, PhD, Head of Biosimilars and Chief Scientific Officer at Teva ...

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a GMP ...

Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing Authorization Application for AVT05, a proposed biosimilar to Simponi, by the European Medicines Agency.

Alvotech (ALVO) has released an update. Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing ...